trial · primary record
Daratumumab
Multiple Myeloma
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 395 |
| Primary completion | 2026-04-21 |
| Primary endpoint | Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate |
| Registry ID | NCT03652064 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:54.701Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03652064
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Daratumumab · approval
- Daratumumab · compound